Literature DB >> 16336031

Issues in treatment-resistant depression.

Martin B Keller1.   

Abstract

Major depressive disorder is a debilitating disease that imposes significant social and economic burdens not only on patients but also on society. Although various treatment options are available, treatment-resistant depression is common. Determining the exact prevalence of treatment-resistant depression is difficult because definitions vary, as do definitions of antidepressant response. Operational definitions of antidepressant response, nonresponse, partial response, and remission will be discussed in this article. Pharmacotherapy options for patients with treatment-resistant depression include augmentation, combination, and switching therapies; however, data from controlled clinical trials supporting these therapies are limited. Electroconvulsive therapy and psychotherapy offer additional treatment strategies. New nonpharmacologic therapies are under investigation. Remission is the goal of treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336031

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  26 in total

1.  Acute relapse after successful vagus nerve stimulation therapy: a case report of last-resort ECT treatment.

Authors:  Liesbeth Santermans; Nathalie Vanderbruggen; Chris Baeken
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  The history and future of deep brain stimulation.

Authors:  Jason M Schwalb; Clement Hamani
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 3.  Treatment-resistant depression and mortality after acute coronary syndrome.

Authors:  Robert M Carney; Kenneth E Freedland
Journal:  Am J Psychiatry       Date:  2009-03-16       Impact factor: 18.112

4.  Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.

Authors:  Shuichi Chiba; Tadahiro Numakawa; Midori Ninomiya; Hyung Shin Yoon; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

5.  Chronic unpredictable intermittent restraint stress disrupts spatial memory in male, but not female rats.

Authors:  Dylan N Peay; Hovhannes M Saribekyan; Priscilla A Parada; Elizabeth M Hanson; Bryce S Badaruddin; Jessica M Judd; Megan E Donnay; Diego Padilla-Garcia; Cheryl D Conrad
Journal:  Behav Brain Res       Date:  2020-01-30       Impact factor: 3.332

6.  Molecular serum signature of treatment resistant depression.

Authors:  Tillmann Ruland; Man K Chan; Pawel Stocki; Laura Grosse; Matthias Rothermundt; Jason D Cooper; Volker Arolt; Sabine Bahn
Journal:  Psychopharmacology (Berl)       Date:  2016-06-20       Impact factor: 4.530

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

8.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

Review 9.  Aripiprazole: in major depressive disorder.

Authors:  Juliane Weber; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.

Authors:  Gabor I Keitner; Steven J Garlow; Christine E Ryan; Philip T Ninan; David A Solomon; Charles B Nemeroff; Martin B Keller
Journal:  J Psychiatr Res       Date:  2008-06-30       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.